The official blog of the Lung Institute.

Lung Institute Expands To Nashville

20 Oct 2014
| Under COPD, Lung Disease, Treatments | Posted by
Nashville Lung Institute

Company Looks to Help Patients with New Facility

Exciting news from the Lung Institute today! The company has opened its doors to a new clinic in Nashville, Tennessee! Patients will now be able to choose from two locations to help treat their pulmonary conditions.

The opening was marked by an official ribbon cutting ceremony from the medical staff, RMS corporate team, and members of the Nashville Chamber of Commerce. With Nashville being a hub for medical technology, this was a prime location to expand the Lung Institute brand. After the current success of treating 400 patients at the clinic in Tampa, FL., the new expansion will bring cellular therapys and innovative medicine to the Nashville area.

Jack Coleman, Jr, MD, is the medical director for the Lung Institute in Nashville. He earned his medical degree from the University of Cincinnati as well as completed his internship and general surgery residency at the institution. Dr. Coleman is Board Certified in Otolaryngology and ensures that all treatments and staff will follow strict standards with the highest excellence in personalized patient care.

“I am very excited about these new facilities opening,” says Dr. Coleman. “The Lung Institute is providing innovative procedures for patients with debilitating conditions and will be a prime location for patients in Nashville.”

About the Lung Institute

Changing the lives of hundreds of people across the nation through the innovative technology of regenerative medicine, the Lung Institute has always committed to providing patients a more effective way to address pulmonary conditions and improve quality of life. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive cellular therapies. These doctors have established a patient treatment plan with the highest concern for patient safety and quality of care.

Cellular Therapy for Lung Disease

The Lung Institute utilizes autologous cells, derived from the patient’s own body for both the venous (blood-derived) stem cell procedures. During these procedures, cells are extracted, isolated and then immediately introduced back into the body where they then divide and replicate into healthy cells specialized to the damaged tissue. Since the treatment uses the body’s own cells, there is a less chance for rejection. Both bone marrow and venous cells have shown anti-inflammatory properties beneficial to patients with lung disease.

If you suffer from a lung disease or know a loved one that disease, then cellular therapy is a viable option. If you have any questions, talk to one of our patient care coordinators today, contact us or call us at 888-745-6697 to schedule a free consultation.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.